JP2019518426A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518426A5
JP2019518426A5 JP2018554110A JP2018554110A JP2019518426A5 JP 2019518426 A5 JP2019518426 A5 JP 2019518426A5 JP 2018554110 A JP2018554110 A JP 2018554110A JP 2018554110 A JP2018554110 A JP 2018554110A JP 2019518426 A5 JP2019518426 A5 JP 2019518426A5
Authority
JP
Japan
Prior art keywords
cancer
mapk
inhibitors
patient
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018554110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518426A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/026941 external-priority patent/WO2017180581A1/en
Publication of JP2019518426A publication Critical patent/JP2019518426A/ja
Publication of JP2019518426A5 publication Critical patent/JP2019518426A5/ja
Pending legal-status Critical Current

Links

JP2018554110A 2016-04-15 2017-04-11 がんの診断及び治療方法 Pending JP2019518426A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323210P 2016-04-15 2016-04-15
US62/323,210 2016-04-15
PCT/US2017/026941 WO2017180581A1 (en) 2016-04-15 2017-04-11 Diagnostic and therapeutic methods for cancer

Publications (2)

Publication Number Publication Date
JP2019518426A JP2019518426A (ja) 2019-07-04
JP2019518426A5 true JP2019518426A5 (https=) 2020-05-28

Family

ID=58606578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554110A Pending JP2019518426A (ja) 2016-04-15 2017-04-11 がんの診断及び治療方法

Country Status (10)

Country Link
US (1) US20190032150A1 (https=)
EP (1) EP3443114A1 (https=)
JP (1) JP2019518426A (https=)
KR (1) KR20180134347A (https=)
CN (1) CN109072311A (https=)
AU (1) AU2017249229A1 (https=)
CA (1) CA3018406A1 (https=)
IL (1) IL262208A (https=)
MX (1) MX2018012471A (https=)
WO (1) WO2017180581A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
JP7379355B2 (ja) * 2017-11-20 2023-11-14 トルレモ セラピューティクス アーゲー 診断方法
WO2020046966A1 (en) * 2018-08-27 2020-03-05 Kura Oncology, Inc. Treatment of adenocarcinomas with mapk pathway inhibitors
CN109609640A (zh) * 2019-01-14 2019-04-12 中国科学院上海高等研究院 Etv4的用途
US20220160714A1 (en) * 2019-03-22 2022-05-26 Icahn School Of Medicine At Mount Sinai Methods for treating colorectal cancer
CN109925316B (zh) * 2019-03-26 2021-09-14 广州医科大学附属第二医院 一种治疗溃疡性结肠炎的药物
WO2021007499A1 (en) * 2019-07-11 2021-01-14 Emory University Combination therapies for managing cancer
WO2021173832A1 (en) * 2020-02-25 2021-09-02 Bolt Biotherapeutics, Inc. Cancer treatment methods
TW202200147A (zh) * 2020-05-26 2022-01-01 韓商韓美藥品股份有限公司 Ｂｅｌｖａｒａｆｅｎｉｂ用於癌症治療
WO2022250431A1 (ko) 2021-05-25 2022-12-01 주식회사 박셀바이오 모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포
CN113318105B (zh) * 2021-05-31 2023-02-03 新乡医学院 含Binimetinib的用于治疗结肠癌的药物组合物及其应用
JPWO2022255401A1 (https=) * 2021-06-03 2022-12-08
CN114085909A (zh) * 2021-11-09 2022-02-25 重庆医科大学 Top1作为宫颈癌标志物和/或治疗靶点的应用
KR102849117B1 (ko) 2022-02-07 2025-08-21 한국화학연구원 흑색종 치료 내성 예측용 trim51 바이오마커 및 이의 용도
WO2023219443A1 (ko) * 2022-05-11 2023-11-16 동아대학교 산학협력단 방광암의 전이성 바이오마커
CN115993455A (zh) * 2022-12-29 2023-04-21 南京医科大学康达学院 Rna结合蛋白nova2作为非小细胞肺癌转移标志物的应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
PL179659B1 (pl) 1994-07-21 2000-10-31 Akzo Nobel Nv Kompozycja cyklicznych nadtlenków ketonów sluzaca do modyfikowania (ko)polimerów zwlaszcza do degradacji polipropylenu PL PL PL PL PL PL PL
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
MX9707453A (es) 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE241986T1 (de) 1997-05-06 2003-06-15 Wyeth Corp Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CN1278176A (zh) 1997-11-06 2000-12-27 美国氰胺公司 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
CA2550361C (en) 2003-12-19 2014-04-29 Prabha Ibrahim Compounds and methods for development of ret modulators
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
US7812143B2 (en) * 2006-03-31 2010-10-12 Memorial Sloan-Kettering Cancer Center Biomarkers for cancer treatment
ES2376771T3 (es) 2006-08-21 2012-03-16 Genentech, Inc. Compuestos aza-benzofuranilo y métodos de utilización
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
KR20090071603A (ko) * 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
EP2099796B1 (en) 2006-11-30 2011-06-01 Genentech, Inc. Aza-indolyl compounds and methods of use
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
EP1980627A1 (en) * 2007-04-13 2008-10-15 Pangaea Biotech, S.A. Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on EGFR/CSF-1/CA IX expression
JP5580735B2 (ja) 2007-06-12 2014-08-27 ジェネンテック， インコーポレイテッド Ｎ−置換アザインドール類及び使用方法
US20130331294A1 (en) * 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
PT2231662E (pt) 2007-12-19 2011-09-12 Genentech Inc 8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
AU2008343065B2 (en) 2007-12-19 2012-04-05 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
NZ586575A (en) 2007-12-21 2012-03-30 Genentech Inc Azaindolizines and methods of use
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
JP6097289B2 (ja) 2011-08-04 2017-03-15 アレイ バイオファーマ、インコーポレイテッド セリン／スレオニンキナーゼインヒビターとしてのキナゾリン化合物
HUE045957T2 (hu) 2011-12-30 2020-01-28 Hanmi Pharm Ind Co Ltd Proteinkináz inhibitor hatású tieno[3,2-d]pirimidin származékok
KR20140114415A (ko) * 2012-01-13 2014-09-26 제넨테크, 인크. Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
HUE053994T2 (hu) 2012-03-01 2021-08-30 Array Biopharma Inc Szerin/treonin kináz inhibitorok
AR092253A1 (es) 2012-08-27 2015-04-08 Array Biopharma Inc Inhibidores de serina/treonina cinasa
JP2015533151A (ja) 2012-10-16 2015-11-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト セリン／スレオニンキナーゼ阻害剤
WO2014152377A1 (en) * 2013-03-14 2014-09-25 Vanderbilt University Methods for classifying and treating adenocarcinomas
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10968484B2 (en) * 2013-03-15 2021-04-06 The Broad Institute, Inc. Methods of identifying responses to map kinase inhibition therapy
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3077401B1 (en) 2013-12-06 2018-04-18 Genentech, Inc. Serine/threonine kinase inhibitors
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
KR102379517B1 (ko) 2013-12-30 2022-03-25 제넨테크, 인크. 세린/트레오닌 키나아제 억제제
JP6642942B2 (ja) 2013-12-30 2020-02-12 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
MY188526A (en) 2014-04-09 2021-12-18 Genentech Inc Process for the manufacturing of medicaments

Similar Documents

Publication Publication Date Title
JP2019518426A5 (https=)
Janowitz et al. Adjuvant therapy in renal cell carcinoma—past, present, and future
Chaft et al. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer
Perri et al. Targeted therapy: a new hope for thyroid carcinomas
EP3195168B1 (en) A method for the identification of immunotherapy-drug combinations using a network approach
JP2018508469A5 (https=)
Abravanel et al. An acquired NRAS Q61K mutation in BRAF V600E-mutant lung adenocarcinoma resistant to dabrafenib plus trametinib
JP2015512612A5 (https=)
Kanda et al. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy
US20140348819A1 (en) Methods of Treating Cancer
Hasbal-Celikok et al. Identification of AKT1/β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment
Powles et al. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial
Akkad et al. Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies
EP3606536A1 (en) Biomarkers indicative of prostate cancer and treatment thereof
Guo et al. Decreased expression of STAT5A predicts poor prognosis in osteosarcoma
You et al. Treatment of BRAF-mutated advanced cutaneous melanoma
Bruera et al. Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
Feng et al. Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAF V600-Mutant Melanoma Patient-Derived Xenografts
Steendam et al. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
Wasylecka-Juszczyńska et al. BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation
Qiu et al. Case report: cetuximab in combination with chemotherapy for the treatment of multifocal hepatic metastases from colorectal cancer guided by genetic tests
Sheng et al. 742P activation of the WNT signaling pathway correlates with innate resistance to immune checkpoint therapies in clear cell renal cell carcinoma
Zou et al. Downregulation of RNA binding protein CIRBP (cold-inducible RNA-binding protein) promotes ovarian cancer progression by regulating MAP2K4 mRNA stability and translation
Dima et al. Using Molecular Subtyping of Pancreatic Ductal Adenocarcinoma for Multimodal Treatment Selection in Resectable Disease
Ahmed A comprehensive bioinformatics analysis of BRAF in cancer